Drugs / Autologous adipose-derived mesenchymal stem/stromal cells (MSC)
Autologous adipose-derived mesenchymal stem/stromal cells (MSC)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03840343 | Oct 2019 → Aug 2020 | diabetic kidney disease, impaired renal function disease, kidney failure, type 1 diabetes mellitus +1 | Mayo Clinic | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous adipose-derived mesenchymal stem/stromal cells (MSC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03840343 ↗ |
| Modality | Cell therapy | “Cell therapy” NCT03840343 ↗ |
| Route | Other | “single kidney, intra-arterial delivery” NCT03840343 ↗ |